跳到正文
原文
STAT Pharma 医药频道· Jason Mast·· 2026-10-01AI 评分32

STAT+: 在上海“科学城”,中国崛起中的生物科技公司向全球推介自身

STAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world

AI 导读

上海“科学城”内,包括 Abbisko 在内的多家中国生物科技公司向全球展示其药物研发效率。Abbisko 联合创始人朱晨表示,该公司一项授权给 Merck KGaA 的药物临床试验在 11 个月内完成,其速度之快甚至促使 Merck 高管询问能否培训其员工。

正文

By Jason Mast

Oct. 1, 2026

General Assignment Reporter

SHANGHAI — The biotech executives appeared triumphant.

It was a balmy, overcast Sunday here in the glimmer-and-glass “Science City” district, and the four leaders were on stage at the ballroom level of the five-star Hilton, joking about how much faster, cheaper, and more efficient drug development was here in China than anywhere else — certainly than the United States. (And God help Europe.)

Zhui Chen, co-founder of the now $6 billion Shanghai-based biotech Abbisko, recalled running a trial on a drug licensed to the German pharma Merck KGaA. Abbisko’s trial finished in 11 months, so quickly that Merck executives asked if Abbisko could train their staff.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com